These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 11255277

  • 1. Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.
    Momi S, Nasimi M, Colucci M, Nenci GG, Gresele P.
    Haematologica; 2001 Mar; 86(3):297-302. PubMed ID: 11255277
    [Abstract] [Full Text] [Related]

  • 2. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
    Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M.
    J Clin Invest; 1998 Feb 01; 101(3):667-76. PubMed ID: 9449701
    [Abstract] [Full Text] [Related]

  • 3. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers.
    Azizi M, Veyssier-Belot C, Alhenc-Gelas M, Chatellier G, Billaud-Mesguish E, Fiessinger JN, Aiach M.
    Br J Clin Pharmacol; 1995 Dec 01; 40(6):577-84. PubMed ID: 8703665
    [Abstract] [Full Text] [Related]

  • 4. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.
    Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M.
    Am J Clin Pathol; 2008 Sep 01; 130(3):446-54. PubMed ID: 18701419
    [Abstract] [Full Text] [Related]

  • 5. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G, Marino P.
    Am Heart J; 2007 Dec 01; 154(6):1085.e1-6. PubMed ID: 18035079
    [Abstract] [Full Text] [Related]

  • 6. [Therapeutic indications of low molecular weight heparins].
    Samama MM, Michaut-Paterno F.
    Arch Mal Coeur Vaiss; 1991 Nov 01; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [Abstract] [Full Text] [Related]

  • 7. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
    Bendayan P, Boccalon H, Dupouy D, Boneu B.
    Thromb Haemost; 1994 May 01; 71(5):576-80. PubMed ID: 8091383
    [Abstract] [Full Text] [Related]

  • 8. [Low molecular weight heparins].
    Kher A, Bara L, Samama M.
    Pathol Biol (Paris); 1986 Jan 01; 34(1):61-9. PubMed ID: 3517772
    [Abstract] [Full Text] [Related]

  • 9. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K, Kitazato KT, Sasaki E, Minamiguchi K, Nagase H.
    Thromb Res; 2003 Jan 01; 112(1-2):83-91. PubMed ID: 15013278
    [Abstract] [Full Text] [Related]

  • 10. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
    Suzuki N, Kitazato K, Takamatsu J, Saito H.
    Thromb Haemost; 1991 Apr 08; 65(4):369-73. PubMed ID: 1647552
    [Abstract] [Full Text] [Related]

  • 11. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice.
    Nagase H, Kitazato KT, Sasaki E, Hattori M, Kitazato K, Saito H.
    Thromb Haemost; 1997 Feb 08; 77(2):399-402. PubMed ID: 9157603
    [Abstract] [Full Text] [Related]

  • 12. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S, Wolz M, Nieszpaur-Los M, Schneider B, Lechner K, Eichler HG, Kyrle PA.
    Thromb Haemost; 1994 Dec 08; 72(6):831-5. PubMed ID: 7740450
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function.
    Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP.
    Thromb Haemost; 1997 Sep 08; 78(3):1142-9. PubMed ID: 9308768
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
    Maddineni J, Hoppensteadt DA, Cornelli U, Manoni M, Fareed J.
    Clin Appl Thromb Hemost; 2007 Jan 08; 13(1):52-64. PubMed ID: 17164496
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin.
    Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Watanabe M, Mochizuki H.
    Thromb Haemost; 1997 Apr 08; 77(4):789-95. PubMed ID: 9134660
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J.
    J Mal Vasc; 1987 Apr 08; 12 Suppl B():68-70. PubMed ID: 2834495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.